Soluble CD40 ligand: A potencial marker of cardiovascular risk;El ligando CD40 soluble: Marcador potencial de riesgo cardiovascular

Revista Clinica Espanola

Volumn 207, Issue 8, 2007, Pages 418-421

  San Miguel Hernandez A ^a   Inglada Galiana, L ^a   Garcia Iglesias R ^a   Alonso Castillejos, N ^a   Martin Gil F J ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CYTOKINE; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIOVASCULAR RISK; DENDRITIC CELL; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; MACROPHAGE; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; THROMBOSIS; X CHROMOSOME;

ACUTE CORONARY SYNDROME; ALANINE; ANGINA, UNSTABLE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CD40 LIGAND; CHROMOSOMES, HUMAN, X; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PYRROLIDINES; RISK FACTORS; THROMBOSIS;

EID: 34548665486     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13108766     Document Type: Article

References (27)

1. Casas Pina T. Mediadores de inflamación de aterosclerosis: el papel del ligando CD40. En: Actualidades en el Laboratorio Clínico. Madrid: AEFA , 2004;2-12.
2. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med. 1999;340:115-26.
3. Aikawa M, Libby P. Mecanismos principales de estabilización de la placa aterosclerótica mediante reducción lipídica. Cardiovascular Risk Factor. 2000;9:105-18.
4. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17:1859-67.
5. Cotran RS, Briscoe DM. Endothelial cells in inflammation. En: Kelly W, Harris E, Ruddy S, Sledge C, editors. Textbook of Rheumatology. Philadelphia: WB Saunders Publishing Co.; 1997. p. 183-98.
6. Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: a novel therapeutic target. J Clin Pharmacol. 1997;37:991-1000.
7. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997;78:200-4.
8. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type I matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation. 1999;99:3103-9.
9. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-6.
10. Martínez Villarreal AM, Montoya Guarín CJ. Moléculas accesorias. Revista Asociación Colombiana Alergia, Asma e Inmunología. 2000; 9. Disponible en: http://www.encolombia.com/medicina/ alergia/alergia9200moleculas-vol4.htm
11. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp 39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72:291-300.
12. Iglesias R, José Lescano A. Síndromes coronarios agudos. Evaluación del riesgo oculto. Rev Costarric Cardiol. 2004;6:31-
13. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers and inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-4.
14. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-35.
15. Bavendiek U, Zirlik A, LaClair S, MacFarlane L, Libby P, Schónbeck U. Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow-Derived Cells. Arterioscler Thromb Vasc Biol. 2005;25:1244-9.
16. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
17. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002;105: 2849-54.
18. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123-8.
19. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. For the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-11.
20. The capture investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-35.
21. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al; for the OPUS-TIMI 16 Investigators. Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. Circulation. 2000;102:149-56.
22. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8.
23. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-20.
24. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-52.
25. Freedman JE. CD40 ligand assessing risk instead of damage? N Engl J Med. 2003;348:1163-5.
26. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-52.
27. Borja Villegas J, Rigau Comas D, Izquierdo Pulido I. Therapeutic criteria in the acute coronary syndrome. Rev Clin Esp. 2004;204:389-90.